ramosetron has been researched along with loperamide in 6 studies
Studies (ramosetron) | Trials (ramosetron) | Recent Studies (post-2010) (ramosetron) | Studies (loperamide) | Trials (loperamide) | Recent Studies (post-2010) (loperamide) |
---|---|---|---|---|---|
194 | 94 | 83 | 1,358 | 196 | 488 |
Protein | Taxonomy | ramosetron (IC50) | loperamide (IC50) |
---|---|---|---|
Cocaine esterase | Homo sapiens (human) | 5.7 | |
Beta-2 adrenergic receptor | Homo sapiens (human) | 3.005 | |
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.5 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.27 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
Histamine H2 receptor | Homo sapiens (human) | 3.081 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.202 | |
Mu-type opioid receptor | Homo sapiens (human) | 0.0014 | |
D(3) dopamine receptor | Homo sapiens (human) | 1.337 | |
Delta-type opioid receptor | Homo sapiens (human) | 0.896 | |
Kappa-type opioid receptor | Homo sapiens (human) | 3.125 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 4.105 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.033 | |
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.239 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.628 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ozaki, A; Sukamoto, T; Yoshidomi, M | 1 |
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M | 1 |
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A | 1 |
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Sasamata, M | 1 |
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Nakata, M; Sasamata, M; Takeuchi, A | 1 |
Morgan, B | 1 |
6 other study(ies) available for ramosetron and loperamide
Article | Year |
---|---|
Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models.
Topics: Animals; Antidiarrheals; Benzimidazoles; Diarrhea; Loperamide; Male; Mice; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin Antagonists | 1999 |
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
Topics: Animals; Benzimidazoles; Carbazoles; Carbolines; Carrier Proteins; Colon; Defecation; Gastrointestinal Agents; Guinea Pigs; Humans; Ion Channels; Irritable Bowel Syndrome; Loperamide; Male; Muscle, Smooth; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Restraint, Physical; Serotonin Antagonists; Stress, Psychological | 2007 |
Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Topics: Animals; Behavior, Animal; Benzimidazoles; Carbazoles; Carbolines; Colon; Colonic Diseases, Functional; Conditioning, Psychological; Corticotropin-Releasing Hormone; Defecation; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Gastrointestinal Transit; Immobilization; Irritable Bowel Syndrome; Loperamide; Male; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Psychological; Time Factors; Treatment Outcome | 2007 |
Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
Topics: Animals; Antidiarrheals; Benzimidazoles; Conditioning, Classical; Defecation; Fear; Irritable Bowel Syndrome; Loperamide; Male; Parasympatholytics; Quinolizines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Physiological; Trimebutine | 2008 |
Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.
Topics: Animals; Antidiarrheals; Benzimidazoles; Carbazoles; Carbolines; Colon; Corticotropin-Releasing Hormone; Defecation; Dose-Response Relationship, Drug; Injections, Intraventricular; Loperamide; Male; Pyridines; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Water | 2008 |
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; Colestipol; Disease Models, Animal; Enteric Nervous System; Female; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Loperamide; Lubiprostone; Male; Mice; Natriuretic Peptides; Peptides; Phenylalanine; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Rifamycins; Rifaximin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Visceral Pain | 2016 |